JMP Securities lowered the firm’s price target on Bicycle Therapeutics to $32 from $44 and keeps an Outperform rating on the shares. Given the accelerating timeline to move BT8009 through registrational trials, the firm removed BT5528 from its models and believes the company will need to manage resources prudently, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCYC:
- Bicycle Therapeutics price target lowered by $3 at Needham, here’s why
- Bicycle Therapeutics price target lowered to $43 from $46 at Needham
- Bicycle Therapeutics to host research and development day
- Bicycle Therapeutics updates clinical programs at first ‘R&D Day’
- Imunon appoints Sebastien Hazard as CMO
